Stockreport

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report
PDF Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents [Read more]